Development of a Bioluminescent Cell-Based Assay to ... - Promega

More documents

Recommendations

Info

Summary of the ADCC Reporter Bioassay Design Features 1. Low variability 2. Engineered effector cells to replace primary NK cells (Jurkat FcgRIIIa/NFAT-RE-luc2) 3. “Cells as reagents”, frozen, thaw-and-use format – consistency & convenience 4. Simplicity and robustness of assay protocol and reagents 5. Broad applicability to use with multiple target cells – suspension or adherent Benefits Demonstrates precision, accuracy, linearity, robustness Can quantify potency and stability of therapeutic Ab drugs Can differentiate differences in relative biological activity of Fc effector function in ADCC MOA that result from small changes in Ab glycosylation Confidential and Proprietary. Not for Further Disclosure. 26
For more information Confidential and Proprietary. Not for Further Disclosure. Neal Cosby, PhD Strategic Marketing Manager Neal.cosby@promega.com Or Custom Order Department COD@promega.com
Page 1 and 2: Development of a Bioluminescent Cel
Page 3 and 4: Signaling pathways activated in eff
Page 5 and 6: Protocol 1. Reference or test antib
Page 7 and 8: FcgRIIIa antibody blocking of ADCC
Page 9 and 10: Bioassay development: Optimizing Ef
Page 11 and 12: Bioassay development: Evaluating cl
Page 13 and 14: Target cells can also be frozen, th
Page 15 and 16: ADCC Reporter Bioassay using frozen
Page 17 and 18: Precision, accuracy and linearity o
Page 19 and 20: ADCC Reporter Bioassay is stability
Page 21 and 22: Additional target cell option: Raji
Page 23 and 24: iological activity of therapeutic a
Page 25: Planned ADCC Reporter Bioassay kit

Development of a Bioluminescent Cell-Based Assay to ... - Promega

Create successful ePaper yourself

Delete template?

Save as template?